Lung Cancer Drug Trial Failed to Reach Goal
Patients with a specific genetic mutation did not see improved survival outcomes in a recent clinical trial.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you generally trust that pharmaceutical companies provide transparent results during new drug development trials?
ArriVent BioPharma announced that its Phase 3 FURVENT trial evaluating firmonertinib for untreated non-small cell lung cancer did not meet its primary endpoint. The study, which included 398 participants globally, aimed to assess progression-free survival in patients with EGFR exon 20 insertion mutations.
Why it matters
The trial results clarify the efficacy profile of this targeted therapy compared to traditional treatment for this specific mutation. The data now undergoing evaluation will help inform the future development strategy for this medication in lung cancer care.
In the Phase 3 FURVENT trial of 398 patients, firmonertinib failed to reach the primary endpoint of progression-free survival when compared to platinum-based chemotherapy. Researchers assessed outcomes via blinded independent central review.
The players
ArriVent BioPharma
A biopharmaceutical company based in Newtown Square, Pennsylvania, focused on identifying and developing treatments for oncological conditions.
The details
The FURVENT study tested once-daily oral doses of 160mg or 240mg of firmonertinib against a control arm receiving platinum-based chemotherapy combined with pemetrexed. Primary endpoint assessment utilized RECIST 1.1 criteria to track tumor progression. Grade 3 or higher treatment-related adverse events were reported at 26% for the 240mg group, 22% for the 160mg group, and 40% for those in the chemotherapy control arm.
Timeline
October 6, 2026: ArriVent announced the FURVENT trial results.
Health Landscape
This development occurs within the broader context of the development landscape for EGFR exon 20 insertion mutant NSCLC therapies, where researchers are seeking alternatives to standard-of-care chemotherapy. It represents a significant departure from expectations for targeted therapies in this space.
Patients currently exploring treatment options for EGFR exon 20 insertion mutant lung cancer should discuss the latest findings with their oncologist to understand how they affect current care plans. Always consult your physician before making any decisions regarding clinical trial enrollment or therapeutic changes.
The takeaway
The FURVENT trial results highlight the ongoing challenges in finding effective targeted therapies for specific lung cancer mutations. Patients should remain in close contact with their oncology teams regarding current standard treatments and any shifts in the clinical evidence base.
Further reading
For more information on current treatment standards, visit the Cancer section.
Live Poll
Do you generally trust that pharmaceutical companies provide transparent results during new drug development trials?
